Scholars Central

Conference abstractPublished 20 Feb 2012

Systems biology approach to cancer metabolomics: Dynamic data analysis through phylogenetics

Authors: Hakima Amri

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The deluge of high throughput data generated by the microarray technologies and mass spectrometry of proteomics and metabolomics has added another level of complexity to biomedical research; reflected mainly in the mining of massively heterogeneous data for biological significance. Two major issues could be considered as contributing factors: (i) the researchers? underestimation of populational heterogeneity and (ii) the lack of adequate bioinformatics paradigms. Consequently, we are still struggling with many unsolved issues, such as the molecular boundaries of disease, class discovery, early detection, treatment response, biomarkers discovery, specimen profiling, unraveling of clonal from non-expanded mutations, genetic versus epigenetic driving events, post-treatment evaluation, and fathoming the primary origin of some cancers. Current analytical methods are unsuitable for the analysis of heterogeneity; they hide intra-populational diversity and homogenizes otherwise heterogeneous subpopulations. Researchers are unaware of alternative biological methods of analysis that take into account individuals? variations. Thus, our phylogenetics model of systems biology offers a universal bioinformatic tool, which meaningfully integrates the heterogeneity of the omics expressions. By modeling cancer types, we revealed developmental pathways, response patterns to cancer therapy, and distinguished aggressive from indolent tumors. It is noteworthy to highlight that phylogenetics offers a dynamic analysis that could lead to early detection, diagnosis, prognosis, as well as to real-time follow-up of the patients? response to treatment, and susceptibility to side effects within each stratum. This data-based modeling paradigm that enables a priori molecular stratification of the study cohort(s) will be presented and its implication for clinical trials design will be emphasized.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Metabolomics:Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMetabolomics:Open Access
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Hakima Amri”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels